Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin a retrospective register study

doi:10.1371/journal.pone.0181000

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Norrving Bo) > Non-vitamin K oral ...

Sjögren, Vilhelm (författare)

Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin a retrospective register study

E-artikel/E-kapitelEngelska2017

Förlag, utgivningsår, omfång ...

PUBLIC LIBRARY SCIENCE2017

Nummerbeteckningar

LIBRIS-ID:21200465
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-138422uri
urn:nbn:se:umu:diva-138422urn
10.1371/journal.pone.0181000doi

Kompletterande språkuppgifter

Språk:engelska

Ingår i deldatabas

deldatabas:Eplk_tEPLK

Anmärkningar

Published
gratis
Background For patients with atrial fibrillation, non-vitamin K oral anticoagulants, or NOACs (dabigatran, rivaroxaban, edoxaban, and apixaban) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, and in risk of haemorrhage. In the pivotal NOAC studies, quality of warfarin treatment was poor with mean time in therapeutic range (TTR) 55-65%, compared with >= 70% in Swedish clinical practice. Methods We compared NOACs (as a group) to warfarin in non-valvular atrial fibrillation, studying all 12,694 patients starting NOAC treatment within the Swedish clinical register and dosing system Auricula, from July 1, 2011 to December 31, 2014, and matching them to 36,317 patients starting warfarin using propensity scoring. Endpoints were thromboembolic events and major bleedings that were fatal or required hospital care. Outcome data were collected from validated Swedish hospital administrative and clinical registers. Results Mean age was 72.2 vs 72.3 years, proportion of males 58.2% vs 57.0%, and mean follow-up time 299 vs 283 days for NOACs and warfarin. Distribution of NOACs was: dabigatran 40.3%, rivaroxaban 31.2%, and apixaban 28.5%. Mean TTR was 70%. There were no significant differences in rates of thromboembolic/thrombotic events or gastrointestinal bleeding. NOAC treated patients had lower rates of major bleeding overall, hazard ratio 0.78 (95% confidence interval 0.67-0.92), intracranial bleeding 0.59 (0.40-0.87), haemorrhagic stroke 0.49 (0.28-0.86), and other major bleeding 0.71 (0.57-0.89). Conclusion For patients with atrial fibrillation, NOACs are as effective for stroke prevention as well-managed warfarin but cause fewer major bleedings.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

Byström, Björn (författare)
Renlund, Henrik (författare)
Svensson, Peter J. (författare)
Oldgren, Jonas (författare)
Norrving, Bo (författare)
Själander, Anders (författare)
Umeå universitetMedicinska fakulteten268483 (utgivare)

Sammanhörande titlar

Del av/supplement till:channel record
Ingår i:VärdpublikationPLoS ONE12:71932-6203

Internetlänk

Hitta via bibliotek

PLoS ONE (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Sjögren, Vilhelm; Byström, Björn; Renlund, Henrik; Svensson, Peter ...; Oldgren, Jonas; Norrving, Bo; visa fler...; Själander, Ander ...; visa färre...

Av lärosätet: Swepub_uni:_t

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se